![David Philip Bloxham](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Philip Bloxham
Chief Tech/Sci/R&D Officer at Celltech Group Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mark Hardy | M | 71 |
Celltech Group Ltd.
![]() Celltech Group Ltd. Financial ConglomeratesFinance Part of UCB SA, Celltech Group Ltd. is an investment holding British company. The company is based in Slough, UK. Celltech Group was founded in 1987. | 20 years |
Yogesh Khatri | M | 58 |
Celltech Group Ltd.
![]() Celltech Group Ltd. Financial ConglomeratesFinance Part of UCB SA, Celltech Group Ltd. is an investment holding British company. The company is based in Slough, UK. Celltech Group was founded in 1987. | 11 years |
Stephen Turley | M | 55 |
Celltech Group Ltd.
![]() Celltech Group Ltd. Financial ConglomeratesFinance Part of UCB SA, Celltech Group Ltd. is an investment holding British company. The company is based in Slough, UK. Celltech Group was founded in 1987. | 7 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Martyn D. Williams | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 14 years |
Seppo Ylä-Herttuala | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 16 years |
Andrew Christie | M | 69 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 3 years |
Charles Spicer | M | 59 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 2 years |
Peter Stephen Keen | M | 66 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 15 years |
Rajan Uppal | M | 62 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
David Prince | M | 73 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 9 years |
Daniel Smith | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
Dominic Tonner | M | 67 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
David Venables | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 3 years |
Iain Ross | M | 71 |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 5 years |
Seri Panglima Sulong Matjeraie | M | 78 |
The University of Southampton
| 4 years |
Philip Maxwell | M | - |
The University of Southampton
| 4 years |
Jamilur Reza Choudhury | M | - |
The University of Southampton
| 3 years |
Mohd Ghazali Mahmood | M | - |
The University of Southampton
| 4 years |
David Bowyer | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 7 years |
Robin Larby | M | - |
The University of Southampton
| 4 years |
Kassim Kolia | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
Russell Banks | M | - |
Ark Therapeutics Group Plc
![]() Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | - |
Roy Franklin | M | 71 |
The University of Southampton
| 4 years |
Kevin Blair | M | - |
The University of Southampton
| 4 years |
Andy Cuttell | M | 77 |
The University of Southampton
| 4 years |
Neil Geoffrey Goulden | M | 70 |
The University of Southampton
| 4 years |
MIKE EDINGTON | M | - |
The University of Southampton
| 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 27 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Philip Bloxham
- Personal Network